Targeting KRAS mutations in cancer using a novel siRNA delivery technology

点击翻译按钮获取中文摘要

Mutations in a gene called KRAS are found in 20% of human cancers but are impossible to target with existing treatments. RNA interference is a promising new way to target genes previously considered undruggable, but there is no way to deliver the molecules required for RNA interference to tumours. We will evaluate the ability of a new nanotechnology based delivery system (antibody targeted minicells) to deliver RNA interference, thereby selectively targeting of KRAS in tumours while avoiding toxicity to normal tissue.